Chemokines that attract both dendritic cells (DC) and lymphocyte effectors can aid in cancer immunotherapy by enlisting host immune cells to recognize tumors of low immunogenicity. CCL21 mediates the recruitment and co-localization of naive lymphocytes and antigen-stimulated DC into T-cell zones of secondary lymphoid organs, facilitating T-cell activation. In this chapter, we discuss CCL21 as a novel agent to boost immune responses against cancer. Based on the findings on CCL21, it is anticipated that rational combinations with other treatment modalities will improve the therapeutic efficacy of this chemokine and antitumor benefit in a broad range of solid tumors.
KeywordsChemokine CCL21 T lymphocytes Dendritic cells Immune activation Anti-tumor immune activity Lung cancer
- Sharma S, et al. Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with Interleukin 7/Herpes Simplex Thymidine Kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Ther. 1997;4:1361–70.CrossRefPubMedGoogle Scholar
- Yousefieh N, et al. Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron. 2009;6:6.Google Scholar